A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma

Previously untreated Stage III, IV, or bulky Stage II mantle cell lymphoma (MCL);

MCL diagnosis must be confirmed by IHC or flow cytometry documenting the following phenotypes: (1)CD19+ (or CD20+); (2) Cyclin D1+ (or evidence of the t(11;14) translocation by cytogenetics or FISH);

Adequate sections from original specimen must be available for pathology review;

>= age 18;

PS=0-2;

Must not have clinical evidence of CNS involvement by lymphoma;

Must not have received prior chemotherapy, radiation, or antibody therapy for lymphoma;

Must not be HIV+;

Must not have >= Grade 2 peripheral neuropathy within 14 days prior to registration;

Must not have known hypersensitivity to bortezomib, boron, or mannitol;

Must not have received other investigational drugs within 14 days of registration;

Must not be pregnant or nursing; confirmation by negative hCG pregnancy test must be obtained prior to registration (pregnancy testing is not required for post-menopausal or surgically sterilized women);

Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method;

No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.

Labs and scans (w/in 28 days prior to registration): Assessment for bidimensionally measurable disease; serum LDH; diagnostic CT scan of the chest and abdomen/pelvis with contrast; PET scan (a PET/CT scan can be done instead of separate PET and CT scans if the CT component is a diagnostic CT w/ contrast).

Labs and scans (w/in 42 days prior to registration): Assessment for non-measurable disease; unilateral bone marrrow aspirate and biopsy for staging; If the biopsy cannot be performed by the aspirate is unequivocally consistent with mantle cell lymphoma, this will be considered adequate for staging purposes